Maruti has improved its sales in the recent past.
Have a Plan B in place if the tide turns against you.
Maruti is expected to post double-digit growth on product launches and good demand for entry-level cars.
.jpg)
Since the cash flows will be impacted in a big way, DLF will have to resort to selling non-core assets in a substantial and significant manner through the next few quarters.
More, many market gurus expect the Sensex to reach 30,000 levels by December and 40,000-45,000 in three to four years.
A financial turnaround with the Etihad partnership and debt restructuring has not fully materialised.
.jpg)
To focus on molecules at advanced stage of development; move to impact 200 scientists.
The Network18 stock is down 4.2 per cent after the declaration of results to Rs 49.50 currently.
US will remain a growth driver, with launches & existing portfolios set to result in 15% growth for FY15.
Expectations of strong results, consistent performance and investors preference for stocks in the defensive space help the sector outshine broader markets.
The Telecom Regulatory Authority of India (Trai) has given its recommendations on the much-awaited issue of spectrum sharing.
Favourable response to launches, recovery in CVs will aid growth.
Bharti'suarterly revenue run rate continues to be hover around the $1.2 billion mar
IT and pharma companies again save the day; mask pain in domestic consumption.
Analysts are divided on the deal valuations. Some say Torrent could have bargained harder, as Sanofi, among others, passed it over.
The sharp fall in the rupee's value against the dollar during the July-September quarter, it turns out, has come as a boon for corporate earnings.
Better margins, lower interest outgo could see the company turn profitable in FY15.
Revival in domestic business should also help overall revenue growth.
Given its track record, cautious analysts are monitoring progress on these fronts.
While domestic sales in the second quarter are expected to be weak for major players, Lupin is likely to outperform the pharma sector on the back of a growing chronic portfolio.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances